- The deployment of the coronavirus vaccine is still a bit bumpy in the US, trapped by everything from states that have to follow complex recipient levels, to the limit.
- Elected President Joe Biden on Friday outlined his plan to significantly improve the effects of COVID vaccines after next week, when he and Vice President-elect Kamala Harris take office.
- Meanwhile, interim findings related to Johnson & Johnson’s coronavirus vaccine trial show important promise, suggesting that another COVID vaccine will soon be authorized in the US.
The news surrounding the coronavirus vaccine continues to grow, and the end of the week brought a number of new developments – including the Trump administration misleading the country over the size of the US vaccine supply to President-elect Biden, who details revealed about its comprehensive national COVID. vaccine strategy. The latter will mean, among other things, that the countries will have to cast complicated levels, and that more vaccination sites and federal resources will be available, so that the vaccination rate will increase dramatically. As for the former, it appears that the Trump administration has lied outright or hurt badly (or a combination of the two) when it comes to U.S. vaccine reserves.
The Trump administration’s secretary of health and human services, Alex Azar, announced on Tuesday that the government “will release the entire stock (vaccine) for order by state, rather than keeping second doses in reserve.” Except, oops – according to a senior administration official. CNN, what reserve we had is already used up. At least the vaccine news isn’t bad – just look at new trial data released in the United States earlier this week New England Journal of Medicine regarding the safety, efficacy, and potential side effects of Johnson & Johnson’s new single-dose coronavirus vaccine.
Today’s Top Deal 
Wear the best-selling Powecom KN95 masks before they are sold out! Price:$ 25.99 
BGR is available at Amazon and may receive a commission Available at Amazon BGR may receive a commission
According to the trial findings, researchers from Johnson and Johnson randomly assigned a little over 800 participants to receive a high or a small dose of the vaccine or a placebo. The results show that at least 90% of the study participants developed neutralizing antibodies after 29 days after vaccination – a figure that grew to 100% 57 days after vaccination.
Some of the side effects of Johnson & Johnson’s COVID vaccine, which will soon be authorized in the US, will include:
- Fever
- Headache / muscle aches
- Fatigue
- Pain at the injection site
And this is so far. Pain at the injection site appears to be the most common side effect among participants in the J&J study. Hopefully this good news helps pave the way for a quick decision on the authorization of Johnson & Johnson’s COVID vaccine for use in the US, where part of the bottleneck was a restrictive restriction of the vaccine supply. ‘Self-imposed’, in the sense that the Trump administration’s mistakes included not buying enough of Pfizer’s coronavirus vaccine to, among other things, make a big dent in the US so far.
Andy is a Memphis reporter who also contributes to outlets such as Fast Company and The Guardian. If he does not write about technology, he can be protective of his budding collection of vinyl, as well as the nursing of his Whovianism and a variety of TV shows that you probably do not like.